Biotechnology – UAH – The University of Alabama in Huntsville

Posted on by

The Graduate Program in Biotechnology Science and Engineering is an Interdisciplinary Program with faculty from the Departments of Chemistry, Biological Sciences and Chemical Engineering. Adjunct faculty from the Marshall Space Flight Center and Hudson Alpha Institute of Biotechnology and companies are also involved in the program.

The program's mission is to provide Ph.D. level graduates who are broadly trained in the areas of science and engineering pertinent to biotechnology and who will benefit the economic, educational, and cultural development of Alabama. Graduates of the program are expected to be able to make significant contributions to biotechnology in academic, governmental, and business settings.

The interdisciplinary program in Biotechnology Science and Engineering provides broad training in sciences and engineering dealing with the handling and the processing of macromolecules and living systems. Students receive advanced training in one of three specializations: Structural Biology, Biomolecular Sciences or Bioprocess Engineering. The principal core of instructors and research advisors are drawn from the Departments of Biological Sciences, Chemistry, and Chemical and Materials Engineering. The program includes significant involvement from local biotechnology companies as well as NASA's Marshall Space Flight Center.

Biotechnology is not a single area of study, but a multidisciplinary field concerned with the practical application of biological organisms and their subcellular components to industrial or service manufacturing, to environmental management and health, and to medicine. It is a series of enabling technologies drawn from the fields of microbiology, cellular biology, molecular biology, genetics, biochemistry, immunology, fermentation technology, environmental science and engineering which allow one to synthesize, breakdown or transform materials to suit human needs. Biotechnology ("Current Trends in Chemical Technology, Business, and Employment," American Chemical Society, Washington, DC. 1998) can therefore be defined as the safe study and manipulation of biological molecules for development of products or techniques for medical and industrial application. Although biotechnology in the broadest sense is not new, the current ability and demand for manipulating living organisms or their subcellular components to provide useful products, processes or services has reached new heights. Modern biotechnology has resulted from scientific scrutiny of old and familiar processes and from new advances in molecular biology, genetic engineering and fermentation technologies.

The future industrial landscape will continue to include research, development and the manufacturing of products such as proteins and nucleic acids that will be based wholly or in large part on biological processes.

Follow this link:
Biotechnology - UAH - The University of Alabama in Huntsville

Roche’s lampalizumab halts geographic atrophy – European Biotechnology

Posted on by

A publication in Science Translational Medicine shows that Roche has a rising star in the 15 million patient market of age-related macular degeneration (AMD). In a Phase II trail US and German researchers showed efficacy in geographic atrophy, an advanced stage of AMD, which has currently no treatment.

One week prior to the publication, Roche announced it has intitiated two Phase III trails (CHROMA and SPECTRI) enroling 936 patients with the advanced form of AMD that affects 5 million AMD patients and has currently no cure. Primary endpoint is slowing for disease progression at 12 months, secondary endpoint is visual acuity at 24 months. However, rumors say the FDA could accelerate patient access through granting breakthrough status to the treatment.

In a multi-center, randomized, 18 month Phase study that recruited 129 AMD patients ( MAHALO), lead author Brian Yaspan observed a 20% reduction in lesion area progression in patients receiving Roche/Genentechs antibody drug candidate lampalizumab at acceptable safety profile. Lampalizumab zeroes in on complement D, part of the innate immune defenses alternative complement pathway

Genome analysis of participants identified a patient subgroup with complement D variants who showed a 44% reduction in geographic atrophy area progression. The authors say targeting the alternative complement pathway has potential to be a viable treatment option for patients with secondary geographic atrophy.

Here is the original post:
Roche's lampalizumab halts geographic atrophy - European Biotechnology

Eli Lilly Unveils $90M Expanded Biotechnology Center in San Diego – Times of San Diego

Posted on by

Share This Article: Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Pharmaceutical giant Eli Lilly announced the completion of a $90 million expansion of its San Diego biotechnology center, which is now more than double its previous size with the addition of 180,000 square feet of work space.

The facility, on Campus Point Drive near UC San Diego, also includes a new high-tech laboratory and room for what the Indianapolis-based company calls a Life Science Studio.

Eli Lilly moved into San Diego in 2004 with the acquisition of Applied Molecular Evolution Inc., and built its Biotechnology Center in 2009.

Being in the San Diego area for the last 13 years has been a game changer for us, specifically in the arena of discovering medicines for hard-to- treat autoimmune conditions, said Thomas F. Bumol, Lillys senior vice president of biotechnology and immunology research.

Company officials said they hope the new facility will allow closer collaboration among researchers. The center originally focused on immunology, but in the larger facility, scientists will also work on diabetes, oncology, neurodegeneration and pain reduction.

Investing in drug discovery and development is critical to maintaining an ecosystem that encourages and promotes innovation, said Jan Lundberg, executive vice president for science and technology and president of Lilly Research Laboratories.

Our expansion in San Diego is a prime example of investing in a research success story, Lundberg said. Expanding our presence in San Diego will not only help us discover and deliver innovative medicines faster, but will also help us achieve our goal of launching 20 new medicines in 10 years.

According to Eli Lilly, the Life Science Studio will allow researchers across the globe to remotely design, synthesize and screen molecules in an unprecedented manner, expanding the ability of scientists to test new ideas, reduce costs and minimize environmental impacts.

City News Service

Eli Lilly Unveils $90M Expanded Biotechnology Center in San Diego was last modified: June 23rd, 2017 by Debbie L. Sklar

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read more here:
Eli Lilly Unveils $90M Expanded Biotechnology Center in San Diego - Times of San Diego

Biotechnology remains a mystery for many Canadians – Western Producer

Posted on by

Canadians generally do not have a solid understanding of what exactly the term biotechnology refers to, according to recently released public opinion research collected by Nielsen Consumer Insights on behalf of Agriculture Canada.

In July 2016, the department issued a contract asking Nielsen Consumer Insights to conduct a comprehensive research project to measure Canadian consumers perceptions and attitudes towards issues related to domestic agriculture and agri-food.

The research would help provide insight while developing the next agriculture policy framework, which comes into force in 2018. The data was collected via a series of focus groups, telephone calls and online consultations.

Overall, researchers found 88 percent of those surveyed have a generally positive or neutral view of biotechnology.

Canadians generally feel that biotechnology will have a positive impact on their future, placing it near the top of a selection of new and emerging technologies in terms of this promise, researchers told Agriculture Canada.

However, Canadian knowledge and view on specific forms of biotechnology varies widely.

Researchers found that most of the people who were surveyed struggled to give examples of biotechnology used in agriculture. Participants typically offered up examples used within the medical and health care fields, such as stem cells, antibiotics and robotics.

The association of the term biotechnology with health applications may be an indication that it is profiting from a halo effect, re-searchers warned.

This could lead to people feeling that biotechnology is positive because the applications that they associate with it promote human well-being.

Researchers reported an aversion to applications of biotechnology that consumers felt had the potential to upset the natural order or would allow scientists to play god.

The closer the application could be seen in terms of living, breathing organisms, the more resistance there was to the specific applications, such as genetically modified animals.

Researchers found less than half (46 percent) of the Canadians surveyed were familiar with the concept of GM animals, which has dropped from previous years.

Canadians werent particularly comfortable with the idea. Many within the focus groups raised moral or ethical concerns about it.

People were much more likely to see the potential risks of GM animals as outweighing the benefits than they were likely to see with other technologies, the report reads.

Those technologies include biofuel, gene editing and genetically modified fish, including fish that could be used to produce insulin for diabetic human patients.

Despite specific consumer concerns around certain applications, researchers found Canadians have not rejected biotechnology all together.

Consumer opinions are built based on the specific use presented and individual knowledge of that particular form of biotechnology, researchers said.

In other words, there does not appear to be a blanket approval or rejection of biotechnologies themselves.

Thats good news for Canadian agriculture, where participants stressed Canada could easily be-come a world leader in the agriculture and food biotechnology re-search field. That conviction, researchers found, is increasing as more attention is paid to it.

It is possible that this is due to the growing role that these technologies are playing in our food supply and a higher level of media attention, Agriculture Canada was told.

Similarly, people agree that these technologies will be developed elsewhere in the world where regulations and control may be less stringent, the report said, which isa situation Canadians said they would like to avoid. The federal government, respondents said, has an important role to play in the biotechnology field.

Over the course of the study, 875 Canadians were contacted last year by phone between Aug. 31 and Sept. 17 and Dec. 1-13. The phone portion of the research has a margin of error of plus or minus 3.3 percent.

Another 220 Canadians participated in the online survey, and 10 focus groups were held, with two meetings each in Toronto, Montreal, Vancouver, Halifax and Calgary.

Kelsey Johnson is a reporter with iPolitics, http://www.ipolitics.ca.

Read more here:
Biotechnology remains a mystery for many Canadians - Western Producer

Play the iShares Nasdaq Biotechnology Index (ETF)’s (IBB) Popularity for Free – Investorplace.com

Posted on by

Wall Street is going gaga over the healthcare and biotech sector. The iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) rallied 9% in four days. TheSPDR S&P Biotech (ETF) (NYSEARCA:XBI) rallied even more.

These are impressive moves that deserve respect. But I cannot chase it if I am not already on board the trade. Or I will end up buying someone elses profits. Wall Street loves to trade memes these days. A few weeks ago the IBB was dead money, now they cant have enough of it.

The hoopla centers around expectations from the new healthcare bill. I think we are giving it too much credit. We dont know if it will pass and even if it does, we dont know its full effects. But I am willing to bet that it wont be better to the sector than Obamacare was. This new bill is likely to be less, and therefore we could have a disappointment period coming.

Click to Enlarge Before you label me a perma-bear, I was a fan of the IBB a few weeks ago. Instead of chasing the momentum after it happens, a bit a good homework delivered great results. Case in point is this massive win from a bullish trade I shared on May 23 which yielded easy profits and out of thin air.

Now that everyone and their sister is chasing this rally in the IBB, I am ready to try and short it. Before you send out the posse to arrest me for daring to short the hot topic du jour, my trade is not against the sector, but rather is my bet against the short-term price action. I like to go long IBB on weakness but here I see the potential for a dip.

A lot of the enthusiasm is tied to politicians doing the right thing, and I am not so sure they will deliver. Even if they do, its probably going to take longer and be less than we expect. Eventually, traders will get antsy and lose interest and the IBB bids will abate, thereby creating a small vacuum below the current steep wedge. Therein lies the opportunity.

The Bearish Bet: Buy the IBB Aug $315/310 debit put spread for $1.50 or better per contract. If price falls through my spread in the next 56 days, I could triple my money. The faster and sooner the fall, the better otherwise time is my enemy.

To mitigate my out-of-pocket risk, I will leverage the value in the IBB ETF. I will sell longer dated puts to finance my bearish bet.

The Bank: Sell IBB Dec $270 puts and collect $5 per contract. This is a bullish trade which has a 90% theoretical chance of success. But if the IBB falls through my short put, then I will own the shares and could accrue losses below $265. But if Wall Street is correct about the political exuberance in the biotech sector, then I really have nothing to worry about. For a smaller risk profile, I could use a credit put spread instead.

Selling options is risky, so I never risk more than I am willing or able to lose.

Learn how to generate income from options here. Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him on Twitter at @racernicand stocktwits at@racernic.

Go here to see the original:
Play the iShares Nasdaq Biotechnology Index (ETF)'s (IBB) Popularity for Free - Investorplace.com

Shawnee Mission West High student wins international biotechnology competition – Kansas City Star

Posted on by

Kansas City Star
Shawnee Mission West High student wins international biotechnology competition
Kansas City Star
Hosted by the Biotechnology Institute, the competition challenges high school students from across the world to find solutions to health care, sustainability and environmental needs through biotechnology. Earlier this year, Smith was chosen along with ...

Here is the original post:
Shawnee Mission West High student wins international biotechnology competition - Kansas City Star

Epigenetic drugs set to boost immunoncology – European Biotechnology

Posted on by

German oncologists have unveiled that market-approved inhibitors of DNA methyltransferases (DMNTi) and histone deacetylases (HDACi) act through expression of cancer neoantigens. They already have a biomarker test to identify responders.

The findings, reported in Nature Genetics, are good news for drug developers who want to broaden the scope of current immune checkpoint modulators through combination therapies that trigger cancer cells to release immunogenic neoantigens.

Following addition of epigenetic inhibitors to cancer cell cultures thousands of atypical transcripts with altered frameshift were expressed form previously ignored endogenous promotors of retroviral origin, resulting in profound tumour cell death, group leader Plass from German Cancer Centre told European Biotechnology. His team has already a biomarker assay that could identify responders to the treatment as it measures activation of the normally silent treatment induced, not-annotated transcription start sites (TINATs).

Up to now, pharma majors such as Roche/Genentech have largely relied on combination of their checkpoint inhibitors with personalised mRNA cancer vaccines. The new findings might open the avenue to a broader activation of cancer neoantigens than these vaccinesas over 2,500 TINATs have been identified in the human genome by the researchers. The retrotransposons (elements of human endogenous retroviruses, HERVs), which are located in long terminal repeats, have entered the human genome millions of years ago.

However, application of the findings might be hampered by the fact that TINATs, so far, have only been identified in the human genome, which might complicate preclinical in-vivo testing. Its unclear if they also exist in animals, says Plass, who is currently deciphering the exact mechanism that normally stops TINATs from being activated. First findings suggest that acetylation of transcription factors might play an important role.

More here:
Epigenetic drugs set to boost immunoncology - European Biotechnology

Lilly Completes $90M Expansion of San Diego Biotechnology Center – Genetic Engineering & Biotechnology News

Posted on by

Eli Lilly has added a new state-of-the-art laboratory and 180,000 square feet of additional working space to its Biotechnology Center in San Diego, CA. Reporting completion of the $90-million expansion, Lilly said the 145% increase in working space will help to foster collaborations with external partners, and allow closer partnerships between its biotechnology, discovery chemistry, and research technology teams. The aim is to accelerate drug discovery within therapeutic areas including immunology, diabetes, oncology, neurodegeneration, and pain.

To further exploit its expertise in automated organic synthesis, and build on its Automated Synthesis Laboratory in Indianapolis, Lilly is also establishing the Lilly Life Science Studio at the San Diego site. The firm says the new facility will give researchers worldwide the ability to remotely test new ideas, and design, synthesize, and screen molecules.

"Investing in drug discovery and development is critical to maintaining an ecosystem that encourages and promotes innovation, commented Jan Lundberg, Ph.D., executive vice president for science and technology and president of Lilly Research Laboratories. "Expanding our presence in San Diego will not only help us discover and deliver innovative medicines faster, but will also help us achieve our goal of launching 20 new medicines in 10 years."

"This year we announced a commitment to invest $850 million in our U.S. operations based on our potential for growth and the company's long-standing investment in the U.S. market, added David A. Ricks, Lilly's chairman, president, and CEO. "This investment doesn't come without risk. America's biopharmaceutical leadership is driven by a free-market economy that rewards innovation. Today, there are multiple public policy threats to our business that would discourage or reduce our investment in the U.S. and the state. We are committed to working with policymakers and stakeholders to ensure our efforts to deliver new innovative medicines to patients are not threatened."

Lilly set up the San Diego Biotechnology Center, which is sited close to the University of California, San Diego, in 2009, having acquired Applied Molecular Evolution back in 2004.

Earlier this month Lilly reported that it will acquire a pipeline of dual amylin calcitonin receptor agonists (DACRAs) from KeyBiosciencefor the potential treatment of type 2 diabetes and other metabolic disorders.

Here is the original post:
Lilly Completes $90M Expansion of San Diego Biotechnology Center - Genetic Engineering & Biotechnology News

Eli Lilly expands Biotechnology center – BSI bureau (press release)

Posted on by

The center features a new technologically-advanced laboratory and an additional 180,000 square feet of working space, which is an increase of 145 per cent compared to the former facility.

Eli Lilly and Company has announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain.

The center features a new technologically-advanced laboratory and an additional 180,000 square feet of working space, which is an increase of 145 per cent compared to the former facility. In addition to the center's established presence in preclinical and clinical immunology research, the new space allows for closer partnership between Lilly experts in biotechnology, discovery chemistry and research technologies while also fostering external collaborations.

As a pioneer in automated organic synthesis, Lilly is creating the Lilly Life Science Studio in San Diego. Building upon Lilly's Automated Synthesis Laboratory in Indianapolis, the new facility will allow researchers across the globe to remotely design, synthesize and screen investigational molecules in an unprecedented manner. Using the power of automation, the Lilly Life Sciences Studio will shape the next generation of drug discovery and expand the reach of individual scientists to test new ideas, while reducing the cost and minimizing the environmental impact of our research activities.

San Diego has long been an important location for Lilly. In 2004 Lilly acquired Applied Molecular Evolution, Inc. before establishing the Lilly San Diego Biotechnology Center in 2009, located near the University of California, San Diego, among other prominent biomedical research institutes. Since its establishment, the center has created more than 100 jobs with more than 200 scientists currently working in various research activities.

Read the original:
Eli Lilly expands Biotechnology center - BSI bureau (press release)

Top Biotech ETFs to Buy – Motley Fool

Posted on by

Investors must be very careful buying stocks of individual biotechnology companies because of the high risks involved. Buying an exchange-traded fund (ETF) that owns many biotechs and closely follows one of the industry's indexes is a smart way to lower risk. Three biotech ETFs stand out as the top choices:

ETF

Net Assets

Net Expense Ratio

Data source: Yahoo! Finance.

Here's what makes these ETFs ones to consider for investors looking to profit from the biotech industry.

Image source: Getty Images.

The iShares Nasdaq Biotechnology is the oldest biotech ETF and the largest in terms of net assets. This ETF was launched in 2001. It tries to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the Nasdaqstock exchange.

Since inception, the iShares Nasdaq Biotechnology ETF has achieved an average annual return of 7.04%. Over the past five years, the ETF has generated an average annual return of 19.15%.

The ETF currently owns shares of 162 biotech companies. Top holdings include Celgene, Amgen, and Biogen. Because the ETF includes several large biotechs that pay dividends, its 0.46% yield ranks as the highest of these three top biotech ETFs.

The SPDR S&P Biotech ETF launched in January 2006. It attempts to generally track the investment results of the S&PBiotechnology Select IndustryIndex and has a relatively low net expense ratio compared with other biotech ETFs.

Since inception, the ETF has generated an average annual return of 13.67%. Over the past five years, it has produced an average annual return of 20.99%.

The number of holdings in the SPDR S&P Biotech ETF currently stands at 99. While the iShares Nasdaq Biotechnology gives greater weight to biotechs with larger market caps, the SPDR S&P Biotech ETF maintains more equalized weights for all stocks. As a result, the ETF's top holding,Clovis Oncology, makes up only 2.91% of total assets held.

The First Trust NYSE Arca Biotech ETF launched in June 2006, less than five months after inception of the SPDR S&P Biotech ETF.The investment objective of the ETF is to replicate as closely as possible the investment results of the NYSE Arca Biotechnology Index.

This ETF claims the best performance of the three since inception, achieving an average annual return of 16.46%. During the past five years, the First Trust NYSE Arca Biotech ETF has generated an average annual return of 19.75%.

The First Trust NYSE Arca Biotech ETF currently holds positions in 30 biotech stocks. Its top holdings include Alnylam Pharmaceuticals, Myriad Genetics, and Regeneron Pharmaceuticals.

If you're looking to get exposure primarily to large biotech stocks, the iShares Nasdaq Biotechnology ETF is probably your best alternative. The top 10 holdings of this ETF comprise almost 60% of total assets. These top holdings, as mentioned earlier, are larger biotechs. Your exposure to smaller biotechs, therefore, is more limited.

If you would prefer to not be as loaded up with bigger biotech stocks, the two other ETFs are probably better choices for you. The SPDR S&P Biotech ETF gives you more diversification, since it holds more than three times the number of stocks as the First Trust NYSE Arca Biotech ETF does.Also, if expenses are a big issue for you, the SPDR S&P Biotech ETF is your best pick.

Keith Speights owns shares of Celgene and SPDR S&P Biotech ETF. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals, Biogen, and Celgene. The Motley Fool has a disclosure policy.

Continued here:
Top Biotech ETFs to Buy - Motley Fool

Puma Biotechnology, Inc. (PBYI): What’s the Story? – StockNewsJournal

Posted on by

NormanObserver.com
Puma Biotechnology, Inc. (PBYI): What's the Story?
StockNewsJournal
Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $80.25, up from yesterday's close by 2.23%. Given the stock's recent action, it ...
How Technical Indicators Have Come Out? Microbot Medical Inc. (MBOT), Puma Biotechnology, Inc. (PBYI)Post Analyst
Marshall Wace North America LP Takes Position in Puma Biotechnology Inc (PBYI)Stock Observer
Royal Bank Of Canada Raises Puma Biotechnology Inc (PBYI) Price Target to $88.00Transcript Daily
The Cerbat Gem -BBNS -Markets Daily -SEC.gov
all 57 news articles »

See the article here:
Puma Biotechnology, Inc. (PBYI): What's the Story? - StockNewsJournal

Peterborough biotechnology startup targeting $50 million in equity financing – Kawartha Media Group

Posted on by

Kawartha Media Group
Peterborough biotechnology startup targeting $50 million in equity financing
Kawartha Media Group
Peterborough biotechnology startup targeting $50 million in equity financing. Community Jun 22, 2017 02:20 by Todd Vandonk Peterborough This Week. Share. Noblegen Inc. CEO and founder Adam Noble and CCO and co-founder Dr. Andressa Lacerda ...
Noblegen Announces the Opening of Its Second Round of Financing: Peterborough-based biotechnology startup ...GlobeNewswire (press release)

all 2 news articles »

View post:
Peterborough biotechnology startup targeting $50 million in equity financing - Kawartha Media Group

AMD: Novartis challenge Regeneron – European Biotechnology

Posted on by

Following shrinking sales for its wet AMD drug Lucentis, Novartis is back with convincing Phase III results of its anti-VEGF-A singe chain antibody fragment brolucizumab. In two pivotal studies the drug proved to be non-inferior to Regeneron/Bayers Eylea (aflibercept).

With 25 million patients affected worldwide, age-related macular degeneration (AMD) is a highly lucrative market. For years, Novartis first-in-class drug Lucentis (ranibizumab) was dominant in the large US market, but now Regenerons competing drug Eylea (aflibercept, 2026 sales: US$3.3bn, +24%) has overtaken Lucentis (2016: US$2bn, -11%) in US sales, mostly because it is not administered once monthly as Lucentis, but once every two months and has a lower price (US$1,850 per intravitreal injection).

However, results of two pivotal Phase III studies suggest Novartis could return to its former leadership with its next generation anti-VEGF-A-antibody fragment brolucizumab, which has to be administered only once quarterly. In both trials, the HAWK and the HARRIER study, brolucizumab met the primary endpoint of non-inferiority versus aflibercept in best corrected visual acuity after 48 weeks of treatment and the secondary endpoint of mean change in visual acuity. Whats more, the two drugs had comparable side-effect profiles. Novartis plans to submit a BLA next year. Analysts say the drug could reach the market in 2019 and achieve peak sales of US$2bn if also approved in diabetic retinopathy.

However, both aflibercept and Lucentis are challenged by off-label use of Avastin (bevacizumab) as the full-length originator of the single chain antibodies ranabizumab and brolucizumab and competitor to Regenerons VEGF-A/PDF fusion protein has been shown to be non-inferior at a 30-fold lower price.

Continued here:
AMD: Novartis challenge Regeneron - European Biotechnology

Global Pharmaceutical & Biotechnology Environmental Monitoring Market 2017 Danaher Corporation, Thermo Fisher … – Aperture Games

Posted on by

The Report describe Pharmaceutical & Biotechnology Environmental Monitoring Introduction, product scope, market overview, opportunities, risk, driving force also to analyze the top manufacturers, with sales, revenue, and price, market type and application, with sales market share and growth rate by type, application, from 2017 to 2022

Global Pharmaceutical & Biotechnology Environmental Monitoring Industry 2017 presents an executive level blueprint of the global Pharmaceutical & Biotechnology Environmental Monitoring market. This is an analytical research report that delves into evaluating the dynamics of the global Pharmaceutical & Biotechnology Environmental Monitoring market drawing reference to the key trends shaping the supply-chain pattern of the industry. To study the exhaustive information sourced from detailed primary and secondary research, the analysts of the report have used industry leading analytical tools such as SWOT analysis and Porters five forces. The observation made from the analysis not only helps analysts to compile a comprehensive report on the global Pharmaceutical & Biotechnology Environmental Monitoring market, but the same also assists them to understand the prevailing competitive landscape of the market.

For a study to be beneficial for stakeholders, it should constitute a detailed research on the market competitiveness. For the purpose of the same, the research report profiles the leading and prominent players in the Pharmaceutical & Biotechnology Environmental Monitoring market. Information pertaining to key strategies adopted by these companies has been obtained from their respective financial reports, and a meticulous study on the market trends that has impacted their plan of action. Results achieved from the strategies is analyzed thoroughly in the report to update stakeholders about the trends impacting the market. Key findings of the report on the global Pharmaceutical & Biotechnology Environmental Monitoring market will also help companies operating in the market to identify the growth opportunities to propel their operations.

To provide a comprehensive report of the global Pharmaceutical & Biotechnology Environmental Monitoring market, the study has segmented it on the basis of product types, applications, end-use industries, and geography. The leading geographic segments is identified in the report, which also studies the prospects exhibited by the emerging regional markets. With an aim of presenting a 360 degree overview of the market, the report studies the growth drivers, market restraints, and opportunities in detail. Based on in-depth study, the report presents refined growth forecasts for the Pharmaceutical & Biotechnology Environmental Monitoring market.

An exhaustive qualitative review of the factors accelerating and restraining the growth of the Pharmaceutical & Biotechnology Environmental Monitoring market and approaching opportunities has been deployed. The Pharmaceutical & Biotechnology Environmental Monitoring market has been analyzed based on applications, geographic distribution, and the substantial factors accountable for the rising demand of the Pharmaceutical & Biotechnology Environmental Monitoring market globally have been detailed in this report. The report covers the global Pharmaceutical & Biotechnology Environmental Monitoring market right from its definition to the numerous categorizations of the market as well as its key end-use applications.

Get Free Sample Report:https://www.fiormarkets.com/report-detail/67105/request-sample

The elementary weaknesses and strengths of the leading vendors coupled with the rate of growth for each of the segments of the Pharmaceutical & Biotechnology Environmental Monitoring worldwide market have been conferred after a complete analysis of past and prospective trends, regulatory needs, and technological innovations.

Go here to see the original:
Global Pharmaceutical & Biotechnology Environmental Monitoring Market 2017 Danaher Corporation, Thermo Fisher ... - Aperture Games

Environmental Defense Fund: Sustainable farming, feeding growing population require biotechnology – Genetic Literacy Project

Posted on by

It is critical that humanity meet the food needs of a growing population and relieve the increasing pressures on natural systems. Environmental Defense Fund supports the coexistence of diverse farming systems to ensure a sustainable future for farmers, society, and our environment. Achieving these goals will require a comprehensive strategy that draws on a wide range of approaches and technologies, including biotechnology.

EDF recognizes the use of biotechnology as a legitimate deployment of science in the search for effective solutions, and also recognizes that past deployment of some biotechnology products has caused legitimate concerns. For that reason, we will support or oppose specific biotechnology products or processes based on transparent assessments of their health, environmental, social, and economic risks and benefits.The risks and benefits of biotechnology products will often vary by organism, geography and other variables, and need to be assessed at relevant temporal and spatial scales.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Our position on biotechnology

Excerpt from:
Environmental Defense Fund: Sustainable farming, feeding growing population require biotechnology - Genetic Literacy Project

Eli Lilly and Company Opens Biotechnology Center in San Diego, California – Area Development Online

Posted on by

News Items

According to company officials, the center features a new technologically-advanced laboratory and an additional 180,000 square feet of working space, which is an increase of 145 percent compared to the former facility.

In addition to the center's established presence in preclinical and clinical immunology research, the new space allows for closer partnership between Lilly experts in biotechnology, discovery chemistry and research technologies while also fostering external collaborations.

Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain, company officials explained.

"This year we announced a commitment to invest $850 million in our U.S. operations based on our potential for growth and the company's long-standing investment in the U.S. market," said David A. Ricks, Lilly's chairman, president and chief executive officer. "Today, as part of that commitment, we are pleased to say our research footprint in San Diego has been expanded."

"Investing in drug discovery and development is critical to maintaining an ecosystem that encourages and promotes innovation. Our expansion in San Diego is a prime example of investing in a research success story," said Jan Lundberg, Ph.D., Executive Vice President for Science and Technology & President of Lilly Research Laboratories. "Expanding our presence in San Diego will not only help us discover and deliver innovative medicines faster, but will also help us achieve our goal of launching 20 new medicines in 10 years."

"Congratulations to Lilly on the expansion of its new Biotechnology Center, which will double its drug research and development in San Diego, create high-quality jobs, and encourage collaboration on groundbreaking therapies that improve patient care and lower costs," said Representative Scott Peters. "San Diego's life sciences industry is changing the face of medicine and companies like Lilly are driving this innovation."

The company said it plans an extensive investment in its U.S. Research and Development. Nearly $250 million of Lilly's $850 million capital investments will be dedicated to supporting its research and development centers around the U.S., including the center in San Diego, in 2017. Lilly's other U.S. research centers are located in Indianapolis, Indiana; Cambridge, Massachusetts; New York, New York; and Philadelphia, Pennsylvania.

In 2017, Lilly plans to spend approximately $5 billion on global R&D, nearly $4 billion of which will be invested in U.S. based programs, including projects with many of California's leading biomedical research institutions.

"This investment doesn't come without risk. America's biopharmaceutical leadership is driven by a free-market economy that rewards innovation," said Ricks. "Today, there are multiple public policy threats to our business that would discourage or reduce our investment in the U.S. and the state. We are committed to working with policymakers and stakeholders to ensure our efforts to deliver new innovative medicines to patients are not threatened."

Here is the original post:
Eli Lilly and Company Opens Biotechnology Center in San Diego, California - Area Development Online

UK biotech records third highest year for investment, study finds – European Pharmaceutical Review

Posted on by

Research has revealed that the biotechnology industry was worth 1.3 billion in 2019, marking its third-highest year for investment.

New research has shown that the UK biotechnology sector was worth 1.3 billion in 2019, which is the third-highest year of investment in the industry since 2012.

The study, conducted by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence, found that since 2012, investment has increased by over 400 percent.

Other findings from the report include:

Steve Bates OBE, Chief Executive of the BIA said: The UK biotech sector continues to chart an ambitious global path the sector is in a very strong position heading into a new decade. Its clear that UK biotech companies remain an attractive investment opportunity for global investors, meaning theres a greater diversity of capital than we saw five years ago. However, while we welcome overseas investment, diversifying the domestic life sciences investor base is critical to capturing the full benefits of this key sector of the UK economy.

Kate Rowley, Investment Director at Bioscience Managers, said: The investment landscape has been perceived as challenging due to both national and global uncertainty but the amount raised by UK biotech companies has continued its upward trend in 2019. Despite the continued uncertainty from the global political arena, there are many who see the opportunity to support life sciences as a worthy investment and these investments should help to underpin growth in the sector in 2020 and beyond.

Read more here:
UK biotech records third highest year for investment, study finds - European Pharmaceutical Review

Is Novavax, Inc. (NVAX) Stock Near the Top or Bottom of the Biotechnology Industry? – InvestorsObserver

Posted on by

Novavax, Inc. (NVAX) is near the top in its industry group according to InvestorsObserver. NVAX gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Novavax, Inc. gets a 76 rank in the Biotechnology industry. Biotechnology is number 24 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 63 means the stock is more attractive than 63 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Novavax, Inc. (NVAX) stock has gained 21.61% while the S&P 500 has fallen -2.35% as of 9:44 AM on Friday, Feb 28. NVAX has gained $2.55 from the previous closing price of $11.80 on volume of 1,278,132 shares. Over the past year the S&P 500 is higher by 4.47% while NVAX has gained 1.77%. NVAX lost -$7.12 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read the rest here:
Is Novavax, Inc. (NVAX) Stock Near the Top or Bottom of the Biotechnology Industry? - InvestorsObserver

Global Marine Biotechnology Market Expected to Grow with a CAGR of 8% During the Forecast Period, 2020-2024 – ResearchAndMarkets.com – Business Wire

Posted on by

DUBLIN--(BUSINESS WIRE)--The "Global Marine Biotechnology Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Global Marine Biotechnology Market 2020-2024

The analyst has been monitoring the global marine biotechnology market and it is poised to grow by USD 2.5 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period.

This report on the global marine biotechnology market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in demand for biofuel. In addition, increasing application of seaweeds is anticipated to boost the growth of the global marine biotechnology market as well.

Key Trends for global marine biotechnology market growth

This study identifies increasing application of seaweeds as the prime reasons driving the global marine biotechnology market growth during the next few years.

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Application

Customer landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/4va2oa

See the original post here:
Global Marine Biotechnology Market Expected to Grow with a CAGR of 8% During the Forecast Period, 2020-2024 - ResearchAndMarkets.com - Business Wire

Insights Into the World’s Red Biotechnology Market, 2017-2019 & 2027 – Emerging Opportunities, Revenue Projections, Leading Players – Yahoo…

Posted on by

DUBLIN, Dec. 17, 2019 /PRNewswire/ -- The "Red Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This study on the red biotechnology market provides readers with a holistic market overview, through an extensive analysis of the market.

The report analyzes the market with regards to the historical and current data to provide a forecast for the period of 2019-2027. Actionable insights and findings pertaining to the red biotechnology market help report readers take major business decisions that support their long-term business growth.

The study includes the compilation of the assessment of significant market dynamics such as key industry trends and major developments carried out by leading players, along with a detailed competitive assessment. The study is divided into key sections to provide readers with an individual understanding of the various aspects of the red biotechnology market.

Key Questions Answered

Key Topics Covered

1. Global Red Biotechnology Market - Preface1.1. Market Definition and Scope1.2. Market Segmentation1.3. Key Research Objectives1.4. Research Highlights

2. Assumptions and Research Methodology2.1. Red Biotechnology Market Definition2.2. Red Biotechnology Market Taxonomy

3. Executive Summary : Global Red Biotechnology Market3.1. Introduction3.1.1. Definition3.1.2. Industry Evolution/Developments3.2. Overview3.3. Market Dynamics3.3.1. Drivers3.3.2. Restrains3.3.3. Opportunities3.4. Global Red Biotechnology Market Analysis and Forecast, 2017-20273.5. Market Revenue Projections (US$ Bn)4. Market Outlook4.1. Pipeline Analysis4.2. Mergers & Acquisitions

5. Global Red Biotechnology Market Analysis and Forecast, by Application 5.1. Introduction5.2. Key Findings/Developments, by Type 5.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Application, 2017-20275.3.1. Biopharmaceutical Production5.3.2. Gene Therapy5.3.3. Pharmacogenomics5.3.4. Genetic Testing5.4. Global Red Biotechnology Market Attractiveness Analysis, by Application

6. Global Red Biotechnology Market Analysis and Forecast, by End-user 6.1. Introduction6.2. Key Findings/Developments, by End-user 6.3. Global Red Biotechnology Market Value (US$ Bn) Forecast, by End-user, 2017-20276.3.1. Pharmaceutical Industry 6.3.2. CMO & CRO6.3.3. Research Institutes6.3.4. Others 6.4. Global Red Biotechnology Market Attractiveness Analysis, by End-user

7. Global Red Biotechnology Market Analysis and Forecast, by Region/sub-Region7.1. Key Findings/Developments 7.2. Global Red Biotechnology Market Value (US$ Bn) Forecast, by Region/Sub-Region, 2017-20277.2.1. North America7.2.2. Europe7.2.3. Asia-Pacific 7.2.4. Latin America7.2.5. Middle East & Africa (MEA)7.3. Global Red Biotechnology Market Attractiveness Analysis, by Region/Sub-Region

8. North America Red Biotechnology Market Analysis and Forecast

9. Europe Red Biotechnology Market Analysis and Forecast

10. Asia-Pacific Red Biotechnology Market Analysis and Forecast

11. Latin America Red Biotechnology Market Analysis and Forecast

12. Middle East & Africa Red Biotechnology Market Analysis and Forecast

13. Competition Landscape13.1. Market Player - Competition Matrix 13.2. Market Share Analysis, by Company (2018)13.3. Company Profiles13.3.1. Pfizer Inc.13.3.2. Biogen Inc.13.3.3. Amgen Inc.13.3.4. AstraZeneca PLC13.3.5. Gilead Sciences Inc.13.3.6. Celgene Corporation13.3.7. F. Hoffmann-La Roche Ltd.13.3.8. Merck KGaA13.3.9. Regeneron Pharmaceuticals Inc.13.3.10. Takeda Pharmaceutical Company Limited

For more information about this report visit https://www.researchandmarkets.com/r/xf6hwp

Story continues

More here:
Insights Into the World's Red Biotechnology Market, 2017-2019 & 2027 - Emerging Opportunities, Revenue Projections, Leading Players - Yahoo...